Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-27 EDT			5-day change	1st Jan Change
1,051 ^USD	-1.71%		+0.62%	+19.65%

11:03am	Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study	MT
06-26	Regeneron Pharmaceuticals, Inc Announces Dupixent® Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine	CI

Declaration of Voting Results by Regeneron Pharmaceuticals, Inc

June 20, 2024 at 04:02 pm

On June 20, 2024, Regeneron Pharmaceuticals, Inc announced that it held its annual general meeting on June 14, 2024, and declared voting results. Accordingly, the shareholder proposal submitted by John Chevedden requesting simple majority voting requirements was approved.

Latest news about Regeneron Pharmaceuticals, Inc.

Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study	05:03am	MT
Regeneron Pharmaceuticals, Inc Announces Dupixent® Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine	06-26	CI
FDA approves Verona Pharma's therapy for 'smoker's lungs'	06-26	RE
Bayer's pharmaceutical unit plans more managerial cuts in Europe, Asia	06-26	RE
Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,170 From $1,060, Buy Rating Maintained	06-25	MT
Declaration of Voting Results by Regeneron Pharmaceuticals, Inc	06-20	CI
Alvotech Enters Commercialization Deal for Eylea Biosimilars with Advanz Pharma	06-18	MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,596,400, According to a Recent SEC Filing	06-17	MT
JPMorgan Adjusts Price Target on Regeneron Pharmaceuticals to $1,150 From $1,050	06-17	MT
Regeneron Pharmaceuticals Says 50% of Patients in Multiple Myeloma Therapy Study Achieved Complete Response	06-17	MT
Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma	06-16	CI
Regeneron Pharmaceuticals Wins Injunctions Against Biosimilars to Eye Disease Drug Eylea	06-14	MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $25,610,229, According to a Recent SEC Filing	06-13	MT
Wells Fargo Adjusts Price Target on Regeneron Pharmaceuticals to $1,125 From $1,050	06-12	MT
RBC Capital Raises Price Target on Regeneron Pharmaceuticals to $1,229 From $1,200, Maintains Outperform Rating	06-12	MT
Sanofi, Regeneron Secure US FDA Nod for Kevzara’s Use in Polyarticular Juvenile Idiopathic Arthritis	06-11	MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:00 AM	06-11
Regeneron, Sanofi Gain FDA Approval for Kevzara to Treat Juvenile Idiopathic Arthritis	06-11	MT
Regeneron, Sanofi Get Expanded FDA OK for Kevzara in Polyarticular Juvenile Idiopathic Arthritis	06-11	DJ
Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Has Approves Kevzara®	06-11	CI
Regeneron Pharmaceuticals Insider Sold Shares Worth $798,821, According to a Recent SEC Filing	06-10	MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,115,422, According to a Recent SEC Filing	06-05	MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 08:30 AM	06-05
RBC Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,185	06-04	MT
FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier	06-03	MT

Chart Regeneron Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,069 USD

Average target price

1,051 USD

Spread / Average Target

-1.65%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REGENERON PHARMACEUTICALS, INC.	+19.65%	115B
VERTEX PHARMACEUTICALS INCORPORATED	+16.13%	122B
ARGENX SE	+21.22%	26.64B
BIONTECH SE	-23.84%	19.91B
GENMAB A/S	-17.47%	16.32B
WUXI APPTEC CO., LTD.	-45.95%	15.52B
BEIGENE, LTD.	-19.28%	15.49B
SAREPTA THERAPEUTICS, INC.	+63.84%	14.83B
NEUROCRINE BIOSCIENCES, INC.	+1.94%	13.67B
INSMED INCORPORATED	+116.04%	11.12B

Bio Therapeutic Drugs